Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery, Targeted Therapy, Immunotherapy, Esophagogastric Juction Cancer
Conditions
Brief summary
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.
Interventions
q1-3W according to physician's preference
q1-3W according to physician's preference
RADIATIONRadiotherpay
40-50Gy/1.8-2.2Gy/20-25f
PROCEDURESurgery
Radical esophagectomy
DRUGImmunotherapy
Anti-PD-1/PD-L1 Antibody
DRUG5-FU Analog based chemotherpay
W1-5 qW or d1-14, q3W according to physician's preference
DRUGNimotuzumab
200-400mg, d1,qW
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18 years； * Esophageal or Esophagogastric cancer； * Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa (AJCC 8th)； * Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences； * ECOG PS score: 0\~1； * Estimated survival time ≥3 months； * Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal to 4,000 G/L; Neutrophil: greater than or equal to 2,000 G/L; Platelets: greater than or equal to 100,000/mm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml/min; AST/ALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit； * Informed consent；
Exclusion criteria
* With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc； * Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer； * Existing active infection such as active tuberculosis and hepatitis； * History of myocardial infarction within the past 6 months or history of ventricular arrhythmia； * Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin； * Participation in other clinical trials currently or within 4 weeks of selection； * Pregnant or lactating females； * Absence of medical records.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | 5 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 1 year, 2 year, 3 year, 5 year | — |
| Number of participants with Acute and late toxicities of radiotherapy,chemotherapy and immunotherapy | 3 months | Acute and late toxicities are evaluated by NCI-CTC version 5.0 |
| Pathological response rate | 3 months | Pathological response were classified into three grades.Grade I signifies that there is little shrinkage in the tumor; only mild regression in the tumor cells is observed under themicroscope. Grade II shows gross reduction in size of the tumor and marked regression in the cancer cells microscopically, yet viable nests of cancer tissue are still visible. Grade III implies complete or almost total resolution of the tumor on exploration, and disappearance of the tumor tissue microscopically; only remnants of degenerated cancer cells can be seen (so-called ghost cancer cells). |
| R0 resection rate | 3 months | — |
| Locoregional recurrence free survival | 1 year, 2 year, 3 year, 5 year | — |
| Distant metastasis free survival | 1 year, 2 year, 3 year, 5 year | — |
Countries
China
Contacts
CONTACTXin Wang, MD
Outcome results
None listed